Mochi Health vs Henry Meds 2026: Which GLP-1 Provider Is Worth It?

Mochi Health vs Henry Meds 2026: Which GLP-1 Provider Is Worth It?

Quick Comparison

	Mochi Health	Henry Meds
Compounded semaglutide	$178/mo ($79 membership + $99 med)	$149/mo all-in
Compounded tirzepatide	$278/mo ($79 membership + $199 med)	$349/mo all-in
Brand-name GLP-1s	✅ Via insurance (PA support included)	❌ Not offered
Consultation model	Video with obesity medicine specialist	Async only
Dietitian access	✅ Included	❌ Not offered
Prescription turnaround	Same-day typical	24–48 hours
States served	49 (not Alabama)	Most states
Non-GLP-1 medications	✅ Topiramate, bupropion, metformin	❌
Rating	4.0/5	3.5/5

---

Mochi Health costs more than Henry Meds for compounded semaglutide — $178/mo versus $149/mo. That $29-per-month gap is real. Over six months it's $174; over a year, $348. For a price-sensitive patient, that math matters.

But the comparison isn't purely about semaglutide. When you expand to tirzepatide, the cost relationship flips: Mochi's $278/mo beats Henry Meds' $349/mo by $71 per month. And when you factor in clinical services — video consultations with board-certified obesity medicine specialists, registered dietitian access, and insurance prior authorization support — the price difference starts to look like a question about what kind of care you actually need.

---

How do Mochi Health and Henry Meds compare on price?

Mochi is cheaper for compounded semaglutide on a per-month basis but more expensive for compounded tirzepatide — which means the "better value" answer depends on which medication you're targeting.

Mochi Health's Two-Part Structure

Mochi charges separately for clinical care and medication. The membership fee ($79/mo) covers your video consultations, dietitian access, follow-up visits, and clinical support. The medication cost is on top of that.

Mochi Component	Monthly Cost	Notes
Membership fee	$79/mo	Video visits, dietitian access, clinical support
Compounded semaglutide	$99/mo	Flat rate at all dose levels
Compounded tirzepatide	$199/mo	Flat rate at all dose levels
Brand Wegovy or Zepbound	Varies (copay)	Mochi handles prior authorization

Total monthly cost:

• Compounded semaglutide: ~$178/mo
• Compounded tirzepatide: ~$278/mo

Flat-rate dosing matters for patients who titrate up. Some compounding platforms charge more at higher doses — a patient starting at $149/mo may find themselves at $299/mo or more at a therapeutic maintenance dose. Mochi's price stays at $99/mo for semaglutide (and $199/mo for tirzepatide) regardless of dose, which eliminates cost surprises as treatment progresses.

Both the membership fee and medication cost are HSA/FSA eligible.

Henry Meds' All-In Pricing

Henry Meds charges one flat monthly price that covers consultation, medication, and shipping.

Henry Meds	Monthly Cost	Notes
Compounded semaglutide	$149/mo	All-in including shipping
Compounded tirzepatide	$349/mo	All-in including shipping

Henry Meds does not offer brand-name Wegovy or Zepbound. No insurance navigation is provided. The price you see is the price you pay.

6-Month Total Cost Comparison

Medication	Mochi Health	Henry Meds	Difference
Compounded semaglutide	$1,068	$894	Henry Meds saves $174
Compounded tirzepatide	$1,668	$2,094	Mochi saves $426

The semaglutide math favors Henry Meds. The tirzepatide math favors Mochi — by a wider margin. If tirzepatide is your target medication, the cheaper-looking option (Henry Meds) actually costs significantly more over a treatment course.

---

Clinical Model: The Central Difference

Feature	Mochi Health	Henry Meds
Consultation type	Live video with specialist	Async questionnaire review
Provider credentials	Board-certified obesity medicine	Licensed providers (general)
Dietitian access	✅ Included	❌
Follow-up visits	✅ Video follow-ups	Provider messaging only
Lab work	Recommended (additional cost)	❌ Not offered
Non-GLP-1 medications	✅ Clinical alternatives available	❌
Insurance/PA navigation	✅ Included	❌

What "Board-Certified Obesity Medicine" Actually Means

Mochi's providers are specialists — physicians who have completed additional training and passed board certification in obesity medicine specifically. This is not a generalist practitioner who handles weight loss among many other conditions. An obesity medicine specialist has a deeper clinical framework for assessing metabolic history, evaluating comorbidities that affect treatment selection, and managing the nuanced titration decisions that GLP-1 therapy requires over time.

Henry Meds uses licensed providers reviewing async questionnaires. These are qualified clinicians, but a 15-minute synchronous video with a specialist and a written questionnaire review are not equivalent clinical tools.

When the Clinical Wrapper Is Worth the Cost

The additional cost of Mochi's clinical model pays off most clearly for patients in specific situations:

Complex health histories. Patients with metabolic comorbidities — insulin resistance, PCOS, thyroid conditions, prior bariatric surgery — benefit from a provider who can factor those conditions into treatment selection and dosing. An async questionnaire review is less equipped to handle clinical nuance.

Previous GLP-1 treatment failures. If you've tried semaglutide and didn't respond adequately, or stopped due to side effects, an obesity medicine specialist is better positioned to analyze what went wrong, adjust the titration approach, or evaluate whether tirzepatide or a non-GLP-1 alternative might be more appropriate.

Insurance situations. If your health insurance covers Wegovy or Zepbound, Mochi's prior authorization support can potentially eliminate your medication cost almost entirely (copay-only). Henry Meds offers no insurance navigation at all — their model assumes cash pay.

Patients who need guidance alongside medication. Registered dietitian access (included in Mochi's membership) helps patients manage protein intake to minimize lean muscle loss during GLP-1 treatment, address GI side effects through dietary adjustments, and develop sustainable eating patterns. For patients who want that support, Mochi is the only one of these two providers who offers it.

When Async Is Enough

Henry Meds' model works well for a specific patient profile. If you have a straightforward medical history, have already researched GLP-1 eligibility and understand the clinical criteria, don't have insurance that covers branded GLP-1s, and simply want affordable access to compounded semaglutide — the clinical extras Mochi provides are overhead you're paying for but may not need.

Henry Meds approves most patients within 24–48 hours with no scheduling required. For a patient who has done their research and wants medication access without additional overhead, that speed is the point.

---

What medications do Mochi Health and Henry Meds offer?

Both Mochi Health and Henry Meds offer compounded medications only (unless your insurance covers brand-name drugs, in which case Mochi handles the prior authorization process). Mochi has a broader menu, including non-GLP-1 alternatives that Henry Meds doesn't carry.

Medication	Mochi Health	Henry Meds
Compounded semaglutide	✅	✅
Compounded tirzepatide	✅	✅
Brand Wegovy (via insurance)	✅ (PA support included)	❌
Brand Zepbound (via insurance)	✅ (PA support included)	❌
Oral semaglutide	❌	❌
Non-GLP-1 alternatives	✅ (topiramate, bupropion, metformin, orlistat)	❌

Not every patient who wants weight loss support is a GLP-1 candidate — contraindications, prior adverse reactions, or patient preference can make alternatives appropriate. A provider willing and clinically equipped to prescribe alternatives when indicated is a sign of individualized care rather than a one-size prescription model.

Pharmacy Quality

Both platforms source from 503A/503B-compliant compounding pharmacies. 503B outsourcing facilities are federally regulated and subject to FDA inspection under current Good Manufacturing Practices (cGMP) — a meaningful quality tier above traditional pharmacy compounding. Patients should understand that compounded formulations are not FDA-approved as finished drug products; the active molecules (semaglutide, tirzepatide) are the same, but the final formulation has not undergone the same approval process as Wegovy or Zepbound.

---

Patient Experience

Mochi Health

• Onboarding: Online health questionnaire → schedule video consultation → same-day treatment decision typical
• Consultations: Live video with obesity medicine specialist; dietitian consultation also available at onboarding
• Ongoing care: Follow-up video visits, medication shipped from partner pharmacy, provider accessible for adjustments
• Shipping: Generally within 2 days of approval
• Support: Higher-touch care model, though patient reports mention variable response times during peak periods

Henry Meds

• Onboarding: Online health assessment → async provider review → prescription decision within 24–48 hours
• Consultations: None — messaging only
• Ongoing care: Provider messaging for dose adjustments; no scheduled follow-ups
• Shipping: Free; timeline not specified but no consistent delay reports
• Support: Lean model by design; limited touchpoints

The speed advantage belongs to Henry Meds for initial approval. The ongoing care depth advantage belongs to Mochi.

---

What is the background of Mochi Health and Henry Meds?

	Mochi Health	Henry Meds
Founded	2022	2021
Company type	Private (seed-stage)	Private
Regulatory issues	Eli Lilly lawsuit dismissed 2025	None reported
Pharmacy model	503B-registered partners	503B-registered partners

In 2025, Eli Lilly filed suit against Mochi Health over compounded tirzepatide marketing. A federal court dismissed the case; Mochi continued operating throughout the proceedings. The lawsuit reflects the broader regulatory tension between pharmaceutical manufacturers and the compounding market — a dynamic that affects every compounded GLP-1 provider, not Mochi specifically.

Both companies are relatively young. Neither has the institutional footprint of Hims (public company, NYSE: HIMS) or Ro (Series D, millions of patients). Patients who weigh platform stability alongside clinical factors should factor that in.

---

Which should you choose: Mochi Health or Henry Meds?

When evaluating "Mochi Health vs Henry Meds which is better," the answer depends almost entirely on what kind of care you need — not just what you'll pay per month.

Choose Mochi Health if:

• You have a complex health history — metabolic comorbidities, previous treatment failures, medications that interact with GLP-1s. A board-certified obesity medicine specialist on video is the right clinical resource here.
• Tirzepatide is your target medication — Mochi is $71/month cheaper than Henry Meds for tirzepatide. Over six months that's $426.
• You have insurance that might cover brand GLP-1s — Mochi's prior authorization support can navigate this for you. Henry Meds doesn't offer this path at all.
• You want dietitian guidance — Mochi includes registered dietitian access. No other provider at this price point does.
• You want clinical flexibility — Mochi can prescribe non-GLP-1 alternatives if you're not a candidate or don't respond to GLP-1 therapy.

Choose Henry Meds if:

• Semaglutide price is your primary concern — $149/mo versus Mochi's $178/mo is $29/month less. Over a year it's $348.
• Your situation is clinically straightforward — BMI qualifies, no major comorbidities, no prior treatment failures. The clinical extras Mochi provides are overhead you won't use.
• You want fast, low-friction access — Henry Meds approves most patients within 24–48 hours with no scheduling required.
• You don't need coaching or clinical guidance — You've researched GLP-1s, understand what to expect, and want medication access without added overhead. For many patients asking "is Henry Meds worth it," the answer is yes if this describes you.
• You don't have insurance coverage — If cash-pay compounded semaglutide is the goal and you don't need insurance navigation, Henry Meds delivers that efficiently.

---

Compounding Disclaimer

Both Mochi Health and Henry Meds prescribe compounded semaglutide and tirzepatide from 503A/503B-compliant pharmacies. Compounded medications are not FDA-approved as finished drug products. The active molecules are the same as FDA-approved Wegovy (semaglutide) and Zepbound/Mounjaro (tirzepatide), but compounded formulations are produced outside the FDA's new drug application process. The FDA has raised concerns about the quality control of some compounding pharmacies, and patients should verify that their provider's partner pharmacies are properly registered. The regulatory landscape around compounded GLP-1 availability continues to evolve based on FDA shortage designations.

---

Frequently Asked Questions

Is Mochi Health or Henry Meds cheaper? For compounded semaglutide, Henry Meds is cheaper at $149/mo vs. Mochi's $178/mo. For compounded tirzepatide, Mochi is significantly cheaper at $278/mo vs. Henry Meds' $349/mo.

Does Henry Meds offer video consultations? No. Henry Meds uses an async-only model — you complete an online health assessment and a provider reviews it without a live appointment. Mochi Health includes video consultations with board-certified obesity medicine specialists.

Is Mochi Health worth the extra cost vs. Henry Meds? For patients with complex health histories, tirzepatide as a target medication, or insurance that may cover brand GLP-1s, yes. For straightforward semaglutide access with no insurance and a clean medical history, Henry Meds is the more efficient choice.

What is the cheapest way to get semaglutide online? Henry Meds and Ro both offer compounded semaglutide at $149/mo — the lowest price among major telehealth platforms. Henry Meds' all-in pricing includes shipping and consultation.

Can I get tirzepatide through Henry Meds? Yes, at $349/mo — but Mochi Health offers compounded tirzepatide at $278/mo, saving $71/month or $426 over six months.

Does Mochi Health accept insurance? Mochi does not bill insurance for the membership fee or compounded medications, but they do provide prior authorization support to help patients access brand-name Wegovy or Zepbound if your insurance covers anti-obesity medications.

Related Resources

• Mochi Health Weight Loss Review — Full Mochi analysis: clinical model, pricing details, patient feedback
• Henry Meds Review — Full Henry Meds analysis: pricing, safety, who it works for
• Ro vs Hims vs Henry Meds for GLP-1 — Three-way comparison of the budget-access tier
• Best Cheapest GLP-1 Providers 2026 — All low-cost compounded GLP-1 options ranked
• Found vs Henry Meds for GLP-1 — Another head-to-head involving Henry Meds